Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Paratek Pharmaceuticals, Inc. (PRTK)

Add PRTK Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/14/2017 8:05:37 AM - Followers: 6 - Board type: Free - Posts Today: 0

Paratek Pharmaceuticals, Inc. 75 Park Plaza Boston, MA 02116 United States 617-807-6600 Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include Omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PRTK News: Statement of Changes in Beneficial Ownership (4) 07/21/2017 04:40:30 PM
PRTK News: Statement of Changes in Beneficial Ownership (4) 07/21/2017 04:36:11 PM
PRTK News: Paratek Pharmaceuticals to Report Second Quarter 2017 Financial Results and Provide Update on Clinical Progress on August 2, ... 07/19/2017 04:01:00 PM
PRTK News: Current Report Filing (8-k) 07/17/2017 04:08:05 PM
PRTK News: Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoi... 07/17/2017 04:01:00 PM
#12   This is a $100+ stock! dooshbag 06/14/17 08:05:36 AM
#11   Where did you get that information? dooshbag 06/07/17 09:03:15 AM
#10   News that this stock is tanking. Pierretp 06/07/17 09:02:52 AM
#9   News that this stock is a scam. Pierretp 06/07/17 07:24:00 AM
#8   This is a scam. Be careful. Pierretp 06/06/17 12:03:09 PM
#7   News! Goldmind 06/03/17 02:47:53 PM
#6   This is a 80 dollar stock!!!!!! Goldmind 06/02/17 01:53:12 PM
#5   Nice Goldmind 06/02/17 01:50:26 PM
#4   Weeeedeeeeeee Goldmind 06/02/17 09:51:12 AM
#3   STRONG BUY!!! Goldmind 06/02/17 08:35:29 AM
#2   PRTK bullish 13.61 stocktrademan 09/04/16 02:24:02 PM
#1   PRTK bearish 13.38 stocktrademan 07/16/16 12:39:44 PM